文献速递白血病

初诊加速期慢性髓性白血病中反应时间对临床结局的影响

The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia.
PubMed 文献 · Am J Hematol · 2020-07-23

该研究纳入75例初诊加速期慢性髓性白血病(CML-AP)患者,33例接受伊马替尼、42例接受第二代酪氨酸激酶抑制剂(2GTKI),中位随访96个月。3个月时达到主要细胞遗传学反应(MCyR)者3年总生存率94%对75%(P=.002),无事件生存率93%对42%(P<.001)。作者认为3个月和6个月的早期反应是长期结局的强决定因素。

要点

  • 3个月达到MCyR者3年OS为94%对75%(P=.002),TFS为98%对73%(P<.001)。
  • 3个月达到MCyR者3年EFS为93%对42%(P<.001),FFS为83%对25%(P<.001)。
  • 最终获得持续MR4.5者中67%在3个月时已获得MCyR。

核心结论

  • 在初诊CML-AP中,3个月和6个月的早期反应是长期结局的强决定因素。

研究设计与样本

  • 研究纳入75例初诊加速期慢性髓性白血病(CML-AP)患者,至少具备1项AP特征:原始细胞≥15%(n=2)、嗜碱性粒细胞≥20%(n=19)、血小板<100×10⁹/L(n=7)、细胞遗传学克隆演变(n=34)或超过1项因素(n=13)。
  • 33例接受伊马替尼,42例接受第二代酪氨酸激酶抑制剂(2GTKI),其中达沙替尼19例、尼洛替尼23例。
  • 采用卡方检验和Kaplan-Meier分析评估3个月和6个月时不同程度分子学和细胞遗传学反应对总体细胞遗传学及分子学反应率、总生存(OS)、无事件生存(EFS)、无转化生存(TFS)和无失败生存(FFS)的影响。

主要发现

  • 中位随访96个月(范围18-224个月),完全细胞遗传学反应总体率为79%,主要分子学反应为71%,MR4.5为59%。
  • 3个月达到主要细胞遗传学反应(MCyR)者(n=49)3年OS为94%对75%(P=.002),TFS为98%对73%(P<.001),EFS为93%对42%(P<.001),FFS为83%对25%(P<.001),均优于3个月未达到MCyR者。
  • 最终获得持续MR4.5者中67%在3个月时已达到MCyR。

临床怎么用

  • 原文结论认为在初诊CML-AP中,3个月和6个月的早期反应是长期结局的强决定因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to describe the impact of time to response on the outcomes of 75 patients with accelerated-phase chronic myeloid leukemia (CML-AP) at diagnosis. Patients had at least 1 feature of AP: blasts ≥15% (n = 2), basophils ≥20% (n = 19), platelets <100 × 109 /L (n = 7), cytogenetic clonal evolution (n = 34), or more than one factor (n = 13). Thirty-three patients received imatinib; 42 received a second-generation tyrosine kinase inhibitor (2GTKI) (19 dasatinib and 23 nilotinib). We used chi-square and Kaplan-Meier analyses to determine the impact of various degrees of molecular and cytogenetic response at early time points (3 and 6 months) on rates of overall cytogenetic and molecular response, overall survival (OS), event-free survival (EFS), transformation-free survival (TFS), and failure-free survival (FFS). After a median follow-up of 96 months (range: 18-224 months), the overall rate of complete cytogenetic response was 79%, of major molecular response, 71%, and of molecular reponse (MR)4.5, 59%. Patients who achieved a major cytogenetic response (MCyR) (n = 49) at 3 months had significantly better 3-year OS (94% vs 75%; P = .002), TFS (98% vs 73%; P < .001), EFS (93% vs 42%; P < .001), and FFS (83% vs 25%; P < .001) rates than patients who did not have MCyR at 3 months. Most (67%) who eventually achieved sustained MR4.5 had achieved MCyR at 3 months. In de novo CML-AP, early response at 3 and 6 months is a strong determinant of long-term outcome.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ohanian M, Kantarjian HM, Shoukier M, et al. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020. PMID: 32557828. doi:10.1002/ajh.25907

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。